Results 101 to 110 of about 494,545 (309)

SCREENING OF HEPATITIS G AND EPSTEIN-BARR VIRUSES AMONG VOLUNTARY NON REMUNERATED BLOOD DONORS (VNRBD) IN BURKINA FASO, WEST AFRICA

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2014
In most sub-Saharan countries screening of blood-transmitted infections includes mainly HIV, HBV, HCV and syphilis. Many viruses such as Hepatitis G (HGV) and Epstein-Barr virus (EBV) which also carry a risk of transmission by blood transfusion raise the
Issoufou Tao   +3 more
doaj  

Detection of Hepatitis C Virus RNA in blood and saliva of transfusion-dependent thalassemia patients diagnosed with Hepatitis C

open access: yesContemporary Clinical Dentistry, 2018
Background: The aim of the current study was to detect hepatitis C virus (HCV) RNA in blood and saliva of a population of patients with thalassemia who have HCV antibody in their serum.
Behzad Hooshmand   +4 more
doaj   +1 more source

The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway. [PDF]

open access: yes, 1998
The X gene product of the human hepatitis B virus (HBx) is a transcriptional activator of various viral and cellular genes. We recently have determined that the production of tumor necrosis factor-alpha (TNF-alpha) by HBV-infected hepatocytes is ...
Armesilla, Angel   +11 more
core   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Table 1-1. National notification and print criteria for hepatitis A, hepatitis B, and hepatitis C [PDF]

open access: yes
Table 1-1 describes the national notification criteria for hepatitis A, hepatitis B, and hepatitis C case statuses, based on the current Council of State and Territorial Epidemiologists (CSTE) Position Statements. This table supports general surveillance

core  

Rheumatology Informatics System for Effectiveness (RISE) Registry Participation Associated with Significant Gains in Quality Measure Performance: An Interrupted Time Series Analysis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To examine the association between participation in a qualified clinical data registry and quality measure performance. Methods We included practices that joined the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry between 2015 – 2021.
Gabriela Schmajuk   +5 more
wiley   +1 more source

Schistosoma mansoni Infection Can Jeopardize the Duration of Protective Levels of Antibody Responses to Immunizations against Hepatitis B and Tetanus Toxoid.

open access: yesPLoS Neglected Tropical Diseases, 2016
BackgroundSchistosomiasis is a disease of major public health importance in sub-Saharan Africa. Immunoregulation begins early in schistosome infection and is characterized by hyporesponsiveness to parasite and bystander antigens, suggesting that a ...
Diana K Riner   +9 more
doaj   +1 more source

Hepatitis C and ageing: a community brief [PDF]

open access: yes, 2014
Executive summary: An estimated 226,700 people in Australia are living with chronic hepatitis C. While the numbers of people estimated to have been infected with hepatitis C has reduced over the past 15 years, the number of people with hepatitis C ...
Jacqui Richmond, Jack Wallace
core  

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant

open access: yesPharmaceutics, 2019
Current vaccine research is mostly based on subunit antigens. Despite the better toxicity profile of these antigens they are often poorly immunogenic, so adjuvant association has been explored as a strategy to obtain a potent vaccine formulation ...
Dulce Bento   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy